CTSU Logo CTSU Logo Home | Contact the CTSU | FAQ | Links
CTSU Logo
Home PagePatients PagePhysicians PageCTSU Registration Process
 
CTSU Active Protocols and Accrual Report
130 protocols found. Listed by cancer typeReport Date: 4/17/2014 5:22:27 PM
Brain Cancer
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A221101
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade GliomaCTSU: 01/08/13
Alliance: 01/08/13
To Date: 5
Target: 330
(10/01/13)
CTSU: 18
(04/17/14)
RTOG-0834
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
PHASE III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup TrialCTSU: 05/08/09
RTOG:
To Date: 62
Target: 1367
(02/24/14)
CTSU: 91
(04/17/14)
Breast Cancer
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A011104
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast CancerCTSU: 07/22/13
Alliance:
To Date: 0
Target: 536
(N.A.)
CTSU: 0
(04/17/14)
A011106
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III StudyCTSU: 10/22/13
Alliance: 10/22/13
To Date: 0
Target: 2820
(N.A.)
CTSU: 3
(04/17/14)
A011202
Lead Group:
 Alliance
AllianceSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant ChemotherapyCTSU: 07/22/13
Alliance: 07/22/13
To Date: 0
Target: 2918
(10/01/13)
CTSU: 6
(04/17/14)
A211201
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Change in Mammographic Density with Metformin Use: A Companion Study to NCIC Study MA.32CTSU: 08/22/12
Alliance: 08/22/12
To Date: 51
Target: 450
(10/01/13)
CTSU: 31
(04/17/14)
A221102
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced ArthralgiasCTSU: 09/07/12
Alliance: 09/07/12
To Date: 2
Target: 224
(10/01/13)
CTSU: 13
(04/17/14)
CALGB-40903
Lead Group:
 Alliance
AllianceNCCTG
CALGB
ACOSOG
*** Alliance Only Study***
Phase II Study Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in SITU (DCIS)
CTSU: 02/22/12
Alliance: 02/15/12
To Date: 24
Target: 106
(10/01/13)
CTSU: 13
(04/17/14)
CALGB-70305
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
***STUDY PERMANENTLY CLOSED TO NEW PATIENT ACCRUAL TO STEP 1 EFFECTIVE SEPTEMBER 3, 2013***
***STUDY NO LONGER OPEN TO NEW SITE PARTICIPATION EFFECTIVE FEBRUARY 15th, 2012***
A Randomized Study to Prevent Lymphedema in Women Treated for Breast Cancer
CTSU: 04/08/09
CALGB: 06/30/06
To Date: 565
Target: 780
(01/03/14)
CTSU: 387
(04/17/14)
E1Z11
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
***THE CAUCASIAN/OTHER RACES COHORT FOR E1Z11 WILL BE CLOSED TO ACCRUAL EFFECTIVE FEBRUARY 24, 2014 ***
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
CTSU: 05/10/13
ECOG: 05/08/13
To Date: 117
Target: 1000
(10/06/13)
CTSU: 288
(04/17/14)
E2108
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast CancerCTSU: 02/28/11
ECOG: 02/08/11
To Date: 152
Target: 368
(10/06/13)
CTSU: 116
(04/02/14)
E2112
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast CancerCTSU: 03/21/14
ECOG: 03/19/14
To Date: N.A.
Target: 600
(N.A.)
CTSU: 0
(04/17/14)
E3108
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
***STUDY WILL TEMPORARILY CLOSE TO ACCRUAL EFFECTIVE June 21, 2013 at 5:00 PM Eastern Time***
A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
CTSU: 10/08/10
ECOG: 09/21/10
To Date: 124
Target: 240
(12/08/13)
CTSU: 27
(04/17/14)
NSABP-B-43
Lead Group:
 NSABP
NSABPSWOG
RTOG
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by LumpectomyCTSU: 11/22/08
NSABP: 11/10/08
To Date: 1619
Target: 2000
(02/24/14)
CTSU: 499
(04/17/14)
NSABP-B-47
Lead Group:
 NSABP
NSABPSWOG
RTOG
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast CancerCTSU: 01/07/11
NSABP: 01/06/11
To Date: 2067
Target: 3260
(10/06/13)
CTSU: 636
(04/17/14)
NSABP-B-51
Lead Group:
 NSABP
NSABPSWOG
RTOG
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant ChemotherapyCTSU: 02/22/13
NSABP: 02/21/13
To Date: N.A.
Target: 1636
(N.A.)
CTSU: 0
(04/17/14)
NSABP-B-52
Lead Group:
 NSABP
NSABPSWOG
RTOG
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen DeprivationCTSU: 12/09/13
NSABP: 12/06/13
To Date: N.A.
Target: 212
(N.A.)
CTSU: 1
(04/17/14)
RTOG-1005
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
***The entire cosmesis subset is closed to further enrollment effective January 9, 2014. The trial as a whole still remains open to accrual.***
A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
CTSU: 06/08/11
RTOG: 05/24/11
To Date: 1438
Target: 2312
(10/07/13)
CTSU: 213
(04/17/14)
S0812
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
***This study will be permanently closed to participants who do not plan to submit core needle biopsies. The study will remain open until further notice, to participants who do plan to submit core needle breast biopsies.***
Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High Risk for Breast Cancer Phase IIB
CTSU: 06/08/13
SWOG: 06/01/13
To Date: 96
Target: 200
(10/04/13)
CTSU: 36
(04/17/14)
S1007
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.CTSU: 01/21/11
SWOG: 01/17/11
To Date: 3671
Target: 9400
(10/04/13)
CTSU: 1133
(04/17/14)
S1202
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast CancerCTSU: 11/08/13
SWOG: 11/01/13
To Date: 4
Target: 294
(11/01/13)
CTSU: 10
(04/17/14)
S1207
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapyCTSU: 11/21/12
SWOG: 11/21/12
To Date: 5
Target: 3500
(10/04/13)
CTSU: 26
(04/17/14)
SCUSF-0806
Lead Group:
 SCUSF
SCUSFSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)CTSU: 01/07/11
SCUSF: 03/01/10
To Date: 398
Target: 468
(02/17/14)
CTSU: 267
(04/17/14)
Z11102
Lead Group:
 Alliance
N/AN/AThis study is open to participation by all CTSU member sites.
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)
CTSU: 07/23/12
Alliance: 07/23/12
To Date: 28
Target: 230
(10/02/13)
CTSU: 22
(04/17/14)
CNS Metastases (see Metastatic Cancer)
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
N107C
Lead Group:
 NCCTG
NCCTGSWOG
RTOG
NSABP
NCIC
GOG
ECOG
CALGB
ACOSOG
A Phase III Trial of Post-Surgical Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain DiseaseCTSU: 07/08/11
NCCTG: 07/08/11
To Date: 84
Target: 192
(10/07/13)
CTSU: 106
(04/17/14)
CNS Neoplasms (Primary Tumor)
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
RTOG-0925
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II GliomaCTSU: 01/08/13
RTOG: 08/25/11
To Date: 50
Target: 170
(02/24/14)
CTSU: 0
(04/17/14)
CNS Primary
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A071101
Lead Group:
 Alliance
N/ARTOG
NCCTG
CALGB
ACOSOG
*** Alliance and RTOG Sites Only***
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND# 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resective Recurrent Glioblastoma Multiforme (GBM)
CTSU: 04/08/13
Alliance: 04/08/13
To Date: 8
Target: 222
(11/01/13)
CTSU: 8
(04/17/14)
E3F05
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
***NEW ACCRUAL TO THIS STUDY IS SUSPENDED EFFECTIVE FEBRUARY 3, 2014***
Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
CTSU: 10/08/09
ECOG: 09/11/09
To Date: 150
Target: 540
(10/06/13)
CTSU: 119
(04/17/14)
N0577
Lead Group:
 NCCTG
NCCTGSWOG
RTOG
NSABP
NCIC
GOG
ECOG
CALGB
ACOSOG
Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic GliomaCTSU: 09/22/09
NCCTG: 09/22/09
To Date: 40
Target: 488
(01/03/14)
CTSU: 20
(04/17/14)
N0872
Lead Group:
 Alliance
N/AN/A***N0872 Will Permanently Close to New Patient Accrual Effective Monday, May 12, 2014 at 5:00pm EST.***
***PRE-REGISTRATION TO PERMANENTLY CLOSE EFFECTIVE Thursday, April 10, 2014 at 5:00 PM EST***
*** Alliance Only Study***
Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma
CTSU: 02/22/12
Alliance: 09/30/09
To Date: 110
Target: 158
(10/01/13)
CTSU: 54
(04/17/14)
Carcinoid
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A021202
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid TumorsCTSU: 05/08/13
Alliance: 05/08/13
To Date: 1
Target: 165
(10/01/13)
CTSU: 7
(04/17/14)
Gastrointestinal Cancer
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A021101
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
***Temporary Suspension of this Study Effective February 4, 2014***
Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study
CTSU: 04/08/13
Alliance: 04/08/13
To Date: 7
Target: 20
(10/01/13)
CTSU: 17
(04/17/14)
CALGB-80702
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancerCTSU: 06/22/10
CALGB: 06/15/10
To Date: 1343
Target: 2500
(10/01/13)
CTSU: 1167
(04/17/14)
CALGB-80802
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)CTSU: 02/22/10
CALGB: 02/15/10
To Date: 252
Target: 480
(10/01/13)
CTSU: 162
(04/17/14)
CALGB-80803
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
Randomized Phase II Trial Of Pet Scan-Directed Combined Modality Therapy In Esophageal CancerCTSU: 02/08/12
CALGB: 07/15/11
To Date: 98
Target: 204
(10/01/13)
CTSU: 46
(04/17/14)
E1208
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular InvasionCTSU: 11/09/09
ECOG: 10/28/09
To Date: 179
Target: 400
(10/06/13)
CTSU: 106
(04/17/14)
E2211
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine TumorCTSU:
ECOG:
To Date: 6
Target: 145
(10/06/13)
CTSU: 14
(04/17/14)
E2212
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the LiverCTSU:
ECOG:
To Date: N.A.
Target: N.A.
(N.A.)
CTSU: 0
(04/17/14)
E7208
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing ChemotherapyCTSU:
ECOG:
To Date: N.A.
Target: N.A.
(N.A.)
CTSU: 0
(04/17/14)
GLNE010
Lead Group:
 Alliance
N/AN/A*** STUDY NO LONGER OPEN TO NEW SITE PARTICIPATION EFFECTIVE AUGUST 10, 2012***
Validation and comparison of biomarkers for the early detection of colorectal adenocarcinoma
CTSU: 04/23/12
Alliance: 09/23/11
To Date: 4662
Target: 6000
(01/03/14)
CTSU: 1381
(04/17/14)
N1048
Lead Group:
 NCCTG
NCCTGSWOG
RTOG
NSABP
NCIC
GOG
ECOG
CALGB
ACOSOG
A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal ExcisionCTSU: 01/13/12
NCCTG: 01/13/12
To Date: 72
Target: 1060
(10/01/13)
CTSU: 112
(04/17/14)
RTOG-0848
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas AdenocarcinomaCTSU: 12/08/09
RTOG: 11/17/09
To Date: 321
Target: 950
(02/24/14)
CTSU: 73
(04/17/14)
RTOG-1010
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal AdenocarcinomaCTSU: 01/07/11
RTOG: 12/30/10
To Date: 344
Target: 480
(10/07/13)
CTSU: 16
(04/02/14)
RTOG-1112
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular CarcinomaCTSU: 05/08/13
RTOG: 04/24/13
To Date: 5
Target: 368
(10/07/13)
CTSU: 0
(04/17/14)
S0820
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)CTSU: 03/08/13
SWOG: 03/01/13
To Date: 4
Target: 1488
(10/04/13)
CTSU: 3
(04/17/14)
S1115
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior ChemotherapyCTSU: 10/08/12
SWOG: 08/20/12
To Date: 58
Target: 133
(10/04/13)
CTSU: 58
(04/17/14)
S1201
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) CancerCTSU: 02/22/12
SWOG: 02/08/12
To Date: 112
Target: 225
(10/04/13)
CTSU: 85
(04/17/14)
Genitourinary Cancer
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A031201
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Trial of Enzalutamide (NSC#766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate CancerCTSU:
Alliance: 11/22/13
To Date: N.A.
Target: 1224
(N.A.)
CTSU: 1
(04/17/14)
A031203
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
*** Alliance Only Study***
Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma
CTSU: 05/08/13
Alliance: 05/08/13
To Date: 6
Target: 150
(10/01/13)
CTSU: 13
(04/17/14)
CALGB-70807
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active SurveillanceCTSU: 01/21/11
CALGB: 12/01/10
To Date: 272
Target: 464
(10/01/13)
CTSU: 158
(04/17/14)
CALGB-90203
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate CancerCTSU: 12/22/06
CALGB: 12/15/06
To Date: 593
Target: 750
(10/01/13)
CTSU: 326
(04/17/14)
CALGB-90601
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
A randomized doubled-blinded phase III study comparing gemcitabine, cisplatin, and bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced transitional cell carcinomaCTSU: 08/07/09
CALGB: 07/15/09
To Date: 356
Target: 500
(10/01/13)
CTSU: 210
(04/17/14)
CITN12-03
Lead Group:
 CITN
N/AN/A***Effective 9/10/13, accrual to this trial is temporarily suspended***
A Phase 2 Study of recombinant glycosylated human interleukin-7 (CYT107) after completion of standard FDA approved therapy with sipuleucel-T (Provenge®) for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
CTSU: 07/31/13
CITN: 07/31/13
To Date: N.A.
Target: 80
(N.A.)
CTSU: 0
(04/17/14)
E2810
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Subjects with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following MetastasectomyCTSU: 08/22/12
ECOG: 08/08/12
To Date: 26
Target: 180
(10/06/13)
CTSU: 30
(04/17/14)
RTOG-0524
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
***STEP 1 OF THIS STUDY CLOSED TO ACCRUAL EFFECTIVE FEBRUARY 22, 2013***
A Phase I/II Trial of a combination of Paclitaxel And Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer
CTSU: 12/08/06
RTOG: 07/26/05
To Date: 76
Target: 88
(05/31/13)
CTSU: 10
(04/17/14)
RTOG-0534
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical ProstatectomyCTSU: 11/21/07
RTOG:
To Date: 1470
Target: 1764
(12/09/13)
CTSU: 57
(04/17/14)
RTOG-0815
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate CancerCTSU: 09/22/09
RTOG: 09/14/09
To Date: 1028
Target: 1520
(10/07/13)
CTSU: 31
(04/17/14)
RTOG-0924
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized TrialCTSU: 07/22/11
RTOG: 07/07/11
To Date: 495
Target: 2580
(01/06/14)
CTSU: 13
(04/17/14)
RTOG-1115
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate CancerCTSU: 05/08/12
RTOG: 05/01/12
To Date: 106
Target: 900
(11/04/13)
CTSU: 13
(04/17/14)
S0931
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.CTSU: 04/08/11
SWOG: 04/01/11
To Date: 541
Target: 1170
(10/04/13)
CTSU: 366
(04/17/14)
S1011
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.CTSU: 08/08/11
SWOG: 08/01/11
To Date: 251
Target: 620
(10/04/13)
CTSU: 200
(04/17/14)
S1216
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate CancerCTSU: 02/08/13
SWOG: 02/01/13
To Date: 106
Target: 1636
(10/04/13)
CTSU: 132
(04/17/14)
Gynecologic Cancer
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
9434
Lead Group:
 Case Western
N/ACase WesternRandomized phase II study of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine® NSC #663249) cisplatin-radiochemotherapy versus intravenous cisplatin-radiochemotherapy in women diagnosed with stage IB-IVA cervical cancer and stage II-IVA vaginal cancerCTSU:
Case Western:
To Date: 6
Target: 73
(12/16/13)
CTSU: 0
(04/17/14)
CITN-05
Lead Group:
 CITN
N/ACITNA Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CarcinomaCTSU: 12/31/13
CITN: 12/31/13
To Date: N.A.
Target: 12
(N.A.)
CTSU: 0
(04/17/14)
GOG-0238
Lead Group:
 GOG
GOGSWOG
RTOG
NSABP
NCIC
NCCTG
ECOG
CALGB
ACOSOG
A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine CorpusCTSU: 11/08/10
GOG: 02/25/08
To Date: 69
Target: 200
(10/07/13)
CTSU: 1
(04/17/14)
GOG-0241
Lead Group:
 GOG
GOGSWOG
RTOG
NSABP
NCIC
NCCTG
ECOG
CALGB
ACOSOG
***ACCRUAL TO THIS TRIAL HAS BEEN SUSPENDED IMMEDIATELY EFFECTIVE OCTOBER 28, 2013***
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent Bevacizumab (NSC #704865, IND #7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian tube Cancer (MEOC)
CTSU: 10/22/10
GOG: 10/12/10
To Date: 16
Target: 332
(10/07/13)
CTSU: 3
(04/17/14)
GOG-0258
Lead Group:
 GOG
GOGSWOG
RTOG
NSABP
NCIC
NCCTG
ECOG
CALGB
ACOSOG
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial CarcinomaCTSU: 07/09/09
GOG: 06/29/09
To Date: 662
Target: 804
(10/07/13)
CTSU: 49
(04/17/14)
GOG-0263
Lead Group:
 GOG
GOGSWOG
RTOG
NSABP
NCIC
NCCTG
ECOG
CALGB
ACOSOG
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic LymphadenectomyCTSU: 04/22/10
GOG: 04/12/10
To Date: 138
Target: 534
(10/07/13)
CTSU: 8
(04/17/14)
GOG-0273
Lead Group:
 GOG
GOGSWOG
RTOG
NSABP
NCIC
NCCTG
ECOG
CALGB
ACOSOG
Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal, or Fallopian Tube CancerCTSU: 05/08/12
GOG: 08/15/11
To Date: 218
Target: 290
(10/07/13)
CTSU: 23
(04/17/14)
GOG-0275
Lead Group:
 GOG
GOGSWOG
RTOG
NSABP
NCIC
NCCTG
ECOG
CALGB
ACOSOG
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic NeoplasiaCTSU: 06/22/12
GOG: 06/14/12
To Date: 9
Target: 384
(10/07/13)
CTSU: 0
(04/17/14)
GOG-0277
Lead Group:
 GOG
GOGSWOG
RTOG
NSABP
NCIC
NCCTG
ECOG
CALGB
ACOSOG
A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) v. Observation for Uterus-Limited, High Grade Uterine LeiomyosarcomaCTSU: 06/08/12
GOG: 06/04/12
To Date: 3
Target: 216
(10/07/13)
CTSU: 0
(04/17/14)
RTOG-0724
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
***STUDY TEMPORARILY CLOSED EFFECTIVE 02/28/2014 at 5:00pm EST***
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
CTSU: 10/08/09
RTOG: 09/16/09
To Date: 79
Target: 400
(02/24/14)
CTSU: 20
(04/17/14)
RTOG-1203
Lead Group:
 RTOG
N/AN/AA Randomized Phase III Study of Standard VS IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)CTSU: 11/28/12
RTOG: 11/28/12
To Date: 35
Target: 281
(10/07/13)
CTSU: 8
(04/17/14)
Head and Neck Cancer
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A091101
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
*** New Patient Accrual Suspended Immediately - Effective, May 29, 2013***
*** Alliance Only Study***
TPF Induction Chemotherapy and Veliparib: A Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
CTSU: 10/22/12
Alliance: 10/22/12
To Date: 4
Target: 110
(12/02/13)
CTSU: 0
(04/17/14)
E1305
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Phase III Randomized Trial of Cisplatin and Docetaxel with or without Bevacizumab In Patients with Recurrent or Metastatic Head and Neck CancerCTSU: 08/20/08
ECOG: 08/08/08
To Date: 301
Target: 400
(10/06/13)
CTSU: 111
(04/17/14)
E1311
Lead Group:
 ECOG
N/AN/AA randomized phase II trial of Afatinib (BIBW2992) as adjuvant therapy following chemoradiation in patients with head and neck squamous cell carcinoma at high risk of recurrenceCTSU: 07/22/13
ECOG:
To Date: 0
Target: 108
(10/06/13)
CTSU: 0
(04/17/14)
E3311
Lead Group:
 ECOG
N/AN/APhase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx CancerCTSU: 07/22/13
ECOG:
To Date: 0
Target: 377
(10/06/13)
CTSU: 1
(04/17/14)
NRG-HN001
Lead Group:
 NRG
RTOGSWOG
NSBAP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
***PRE-ACTIVATION: This Trial is Not Yet Open to Patient Enrollment***
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
CTSU: 04/07/14
NRG:
To Date: N.A.
Target: N.A.
(N.A.)
CTSU: 0
(04/17/14)
RTOG-0920
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck CancerCTSU: 11/23/09
RTOG: 11/05/09
To Date: 335
Target: 700
(10/07/13)
CTSU: 29
(04/17/14)
RTOG-1008
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland TumorsCTSU: 08/08/11
RTOG: 11/03/10
To Date: 70
Target: 120
(10/07/13)
CTSU: 4
(04/17/14)
RTOG-1016
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
***The quality of life (QOL) component has met its accrual objective (400 patients) and closed to accrual on 02/28/13. The trial remains open to accrual to the treatment and translational research components.***
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
CTSU: 06/22/11
RTOG: 06/09/11
To Date: 744
Target: 834
(12/09/13)
CTSU: 21
(04/17/14)
RTOG-1216
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Cetuximab and Docetaxel for High-Risk Squamous Cell Cancer of the Head and NeckCTSU: 03/18/13
RTOG: 03/18/13
To Date: 9
Target: 675
(10/07/13)
CTSU: 2
(04/17/14)
RTOG-1221
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx CancerCTSU: 11/13/13
RTOG: 10/30/13
To Date: N.A.
Target: 144
(N.A.)
CTSU: 0
(04/17/14)
Leukemia
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
8854
Lead Group:
 WCMC
N/AWCMCRandomized Phase II Study of Epigenetic Priming Using Decitabine with Induction Chemotherapy in Patients with Acute Myelogenous Leukemia (AML)CTSU: 09/21/12
WCMC: 08/16/12
To Date: 46
Target: 180
(12/09/13)
CTSU: 68
(04/17/14)
A041202
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)CTSU: 10/22/13
Alliance: 10/22/13
To Date: N.A.
Target: 523
(N.A.)
CTSU: 15
(04/17/14)
CALGB-10701
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
A Phase II Study of Dasatinib (Sprycel) (IND #73969, NSC #732517) as Primary Therapy followed by Transplantation for Adults = 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOGCTSU: 05/22/12
CALGB: 12/15/10
To Date: 34
Target: 66
(10/01/13)
CTSU: 11
(04/17/14)
E1910
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in AdultsCTSU: 12/23/13
ECOG: 12/17/13
To Date: N.A.
Target: 360
(N.A.)
CTSU: 0
(04/17/14)
E1912
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)CTSU: 02/07/14
ECOG: 01/31/14
To Date: N.A.
Target: 519
(N.A.)
CTSU: 3
(04/17/14)
E2905
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic AnemiaCTSU: 02/09/09
ECOG: 01/29/09
To Date: 146
Target: 252
(10/06/13)
CTSU: 78
(04/17/14)
E2906
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytosine Arabinoside Induction and Intermediate Dose Cytosine Arabinoside Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age Greater Than or Equal to 60 Years).CTSU: 02/24/11
ECOG: 12/28/10
To Date: 408
Target: 747
(10/06/13)
CTSU: 173
(04/17/14)
E3903
Lead Group:
 ECOG-ACRIN
N/AN/A CTSU:
ECOG-ACRIN:
To Date: N.A.
Target: N.A.
(N.A.)
CTSU: 0
(04/17/14)
S1117
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
***Study Temporarily Closed Effective 4/15/14 at 11:50 pm PST***
A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
CTSU: 03/08/12
SWOG: 03/01/12
To Date: 166
Target: 267
(10/04/13)
CTSU: 184
(04/17/14)
S1203
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-701852) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)CTSU: 02/22/13
SWOG: 02/19/13
To Date: 84
Target: 784
(10/04/13)
CTSU: 122
(04/17/14)
Lung Cancer
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
CALGB-140503
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung CancerCTSU: 07/09/07
CALGB: 06/15/07
To Date: 429
Target: 1258
(10/01/13)
CTSU: 336
(04/17/14)
CALGB-30610
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and EtoposideCTSU: 03/21/08
CALGB: 03/15/08
To Date: 331
Target: 729
(10/01/13)
CTSU: 250
(04/17/14)
CALGB-30901
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
Randomized phase II study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapyCTSU: 09/22/11
CALGB: 04/15/10
To Date: 34
Target: 96
(09/03/13)
CTSU: 21
(04/17/14)
CALGB-31102
Lead Group:
 Alliance
AllianceNCCTG
CALGB
ACOSOG
***Cohort 4 was opened to accrual effective December 4, 2013***
***Study Temporarily Suspended Effective October 17, 2013***
***Limited Participation Study***
Phase I Study of Accelerated Hypofractionated Radiation Therapy with Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
CTSU: 05/22/12
Alliance: 02/15/12
To Date: 18
Target: 24
(10/01/13)
CTSU: 3
(04/17/14)
E1512
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLCCTSU:
ECOG:
To Date: N.A.
Target: N.A.
(N.A.)
CTSU: 0
(04/17/14)
E2511
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung CancerCTSU:
ECOG:
To Date: N.A.
Target: N.A.
(N.A.)
CTSU: 0
(04/17/14)
E5508
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed or Both Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Stage Non-Squamous Non-Small Cell Lung CancerCTSU: 08/23/10
ECOG: 08/12/10
To Date: 788
Target: 1282
(10/06/13)
CTSU: 400
(04/17/14)
RTOG-1306
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)CTSU: 11/04/13
RTOG: 11/04/13
To Date: 0
Target: 234
(10/07/13)
CTSU: 1
(04/17/14)
RTOG-1308
Lead Group:
 RTOG
RTOGSWOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLCCTSU: 12/09/13
RTOG: 11/26/13
To Date: N.A.
Target: 560
(N.A.)
CTSU: 0
(04/17/14)
S0819
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)CTSU: 07/22/09
SWOG: 07/15/09
To Date: 1139
Target: 1546
(10/04/13)
CTSU: 559
(04/17/14)
Lymphoma
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
9177
Lead Group:
 NCIMET
N/AMDA CCOPs
DFCI
CALGB
AMC
***Effective February 26, 2014 enrollment to the MYC positive DLBCL arm of the study (including plasmablastic lymphoma) is halted as the accrual target has been met. The study remains open for patients with untreated Burkitt lymphoma.***
Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma
CTSU: 04/13/12
NCIMET: 04/13/12
To Date: 66
Target: 135
(10/07/13)
CTSU: 95
(04/17/14)
A051103
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
***Limited Access Study, Available Only to the Institutions Specified on the Protocol Cover Page***
A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular lymphoma
CTSU: 04/22/13
Alliance: 04/22/13
To Date: 1
Target: 33
(08/01/13)
CTSU: 0
(04/17/14)
A051201
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
***Temporary Accrual Suspension Effective January 28, 2014***
*** Alliance Study: Phase I Select Site Participation - Phase II Available to Alliance Sites Only***
A Phase I/Randomized Phase II Trial of Idelalisib, Lenalidomide, and Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma
CTSU: 05/22/13
Alliance: 05/22/13
To Date: 0
Target: 18
(10/01/13)
CTSU: 0
(04/17/14)
A051202
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
***Study Temporarily Closed to New Patient Accrual Effective January 23, 2014***
***Limited Access Study, Available Only to the Institutions Specified on the Protocol Cover Page***
A Phase I Trial of Lenalidomide, Rituxima, and Idelalisib in Recurrent Follicular Lymphoma
CTSU: 05/08/13
Alliance: 05/08/13
To Date: 6
Target: 30
(12/02/13)
CTSU: 0
(04/17/14)
CALGB-50801
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
*** Alliance Only Study***
A Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
CTSU: 08/22/13
Alliance: 05/15/10
To Date: 0
Target: 123
(10/01/13)
CTSU: 0
(04/17/14)
CALGB-50904
Lead Group:
 Alliance
AllianceN/A*** Alliance Only Study***
A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lymphoma
CTSU: 04/23/12
Alliance: 04/08/11
To Date: 53
Target: 130
(10/01/13)
CTSU: 14
(04/17/14)
CALGB-51101
Lead Group:
 CALGB
CALGBSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
ACOSOG
A Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell LymphomaCTSU: 06/22/12
CALGB: 06/15/12
To Date: 15
Target: 160
(10/01/13)
CTSU: 1
(04/17/14)
E1411
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ¿ R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV¿ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ¿ LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ¿ LR)CTSU: 06/08/12
ECOG: 05/22/12
To Date: 51
Target: 332
(10/06/13)
CTSU: 49
(04/17/14)
E1412
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell LymphomaCTSU: 01/22/14
ECOG: 08/27/13
To Date: N.A.
Target: 220
(N.A.)
CTSU: 0
(04/17/14)
S1001
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)CTSU: 11/08/11
SWOG: 07/18/11
To Date: 55
Target: 155
(10/04/13)
CTSU: 25
(04/17/14)
Melanoma
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
8443
Lead Group:
 MSKC
MSKCUCC
OSU-CSM
MPC
MMC
HLMCC-CSM
Randomized Phase II Trial of Temozolomide versus Hyd-sulfate AZD624 [NSC 748727] in Patients with Metastatic Uveal MelanomaCTSU: 10/22/10
MSKC: 06/02/10
To Date: 102
Target: 159
(12/09/13)
CTSU: 152
(04/17/14)
A091201
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
*** Alliance Only Study***
Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
CTSU: 05/22/13
Alliance: 05/22/13
To Date: N.A.
Target: 69
(N.A.)
CTSU: 4
(04/17/14)
CITN-04
Lead Group:
 CITN
N/AN/AA Phase II Pilot Trial of an Indoleamine2,3, dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients with Advanced MelanomaCTSU: 09/13/13
CITN: 09/13/13
To Date: N.A.
Target: 12
(N.A.)
CTSU: 0
(04/17/14)
CITN-06-ALT-803
Lead Group:
 CITN
N/ACITNA Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced MelanomaCTSU: 04/01/14
CITN:
To Date: N.A.
Target: N.A.
(N.A.)
CTSU: 0
(04/17/14)
CITN11-02
Lead Group:
 CITN
N/AN/AA Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck CancerCTSU:
CITN:
To Date: N.A.
Target: 20
(N.A.)
CTSU: 0
(04/17/14)
E1609
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
***ARM A OF E1609 WILL BE CLOSED TO ACCRUAL EFFECTIVE APRIL 4, 2014 AT 5PM ET***
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
CTSU: 06/08/11
ECOG: 05/25/11
To Date: 1156
Target: 1500
(10/06/13)
CTSU: 855
(04/02/14)
E2607
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal MelanomasCTSU: 11/22/11
ECOG: 05/01/09
To Date: 72
Target: 87
(10/06/13)
CTSU: 8
(04/17/14)
N0879
Lead Group:
 Alliance
N/AN/A*** Alliance Only Study***
A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma
CTSU: 06/22/12
Alliance: 04/09/10
To Date: 132
Target: 148
(10/01/13)
CTSU: 19
(04/17/14)
Multiple Cancers
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
8233
Lead Group:
 MPC
N/AUCD-CSM
UCC
PMHC
OSU-CSM
MSKCC
MMC
MDAC
HLMCC-CSM
A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell CancerCTSU: 09/08/19
MPC: 09/08/09
To Date: 183
Target: 299
(12/09/13)
CTSU: 249
(04/17/14)
Myeloma
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A061202
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
*** Alliance Only Study***
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
CTSU: 12/09/13
Alliance: 12/08/13
To Date: N.A.
Target: 132
(N.A.)
CTSU: 0
(04/17/14)
E1A11
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple MyelomaCTSU: 11/22/13
ECOG: 11/13/13
To Date: N.A.
Target: 756
(N.A.)
CTSU: 4
(04/17/14)
E3A06
Lead Group:
 ECOG
ECOGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
CALGB
ACOSOG
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic Smoldering Multiple MyelomaCTSU: 11/08/10
ECOG: 11/01/10
To Date: 63
Target: 380
(10/06/13)
CTSU: 21
(04/17/14)
S1211
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)CTSU: 10/02/13
SWOG: 10/01/13
To Date: N.A.
Target: 110
(N.A.)
CTSU: 4
(04/17/14)
S1304
Lead Group:
 SWOG
SWOGRTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory DiseaseCTSU: 11/05/13
SWOG: 10/18/13
To Date: N.A.
Target: 140
(N.A.)
CTSU: 4
(04/16/14)
Sarcoma
Protocol IDMust Enroll through Own GroupCan Enroll through CTSU.
Endorsement:
(*) - Regular
(E+) - Plus
Protocol TitleActivation DateProtocol Accrual
A091102
Lead Group:
 Alliance
N/ANCCTG
CALGB
ACOSOG
***NOTICE OF PERMANENT CLOSURE FOR COHORT 4***
***NOTICE OF PERMANENT CLOSURE FOR COHORT 2***
***COHORT 5 WAS SUSPENDED TO NEW PATIENT ACCRUAL EFFECTIVE SEPTEMBER 30, 2013***
***COHORT 3 WAS SUSPENDED TO NEW PATIENT ACCRUAL EFFECTIVE JULY 25, 2013***
***COHORT 2 WAS SUSPENDED TO NEW PATIENT ACCRUAL EFFECTIVE FRIDAY, 03/22/2013 at Midnight EDT ***
***COHORT 1 WAS TEMPORARILY SUSPENDED EFFECTIVE THURSDAY, 01/17/2013***
*** Alliance Only Study***
A Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
CTSU: 08/22/12
Alliance: 08/22/12
To Date: 72
Target: 135
(10/01/13)
CTSU: 25
(04/17/14)
A091105
Lead Group:
 Alliance
N/ASWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)CTSU: 02/21/14
Alliance: 02/21/14
To Date: N.A.
Target: 83
(N.A.)
CTSU: 0
(04/17/14)
AEWS1031
Lead Group:
 COG
COGSWOG
RTOG
NSABP
NCIC
NCCTG
GOG
ECOG
CALGB
ACOSOG
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing SarcomaCTSU: 12/08/10
COG: 11/22/10
To Date: 364
Target: 630
(02/18/14)
CTSU: 1
(04/17/14)